- Patients with locally advanced or metastatic chordoma with confirmed diagnosis in a reference pathology (with immunohistology for epithelial membrane antigen, S100, Brachyury, Integrase interactor 1 (INI-1)) who have no response or have lost response to treatment with a tyrosine kinase inhibitor e.g. imatinib, lapatinib, erlotinib, sunitinib, sorafenib, etc.